KHPG(SZ:002773) Zheng Quan Zhi Xing·2025-08-04 16:35Core Viewpoint - Chengdu Kanghong Pharmaceutical Group Co., Ltd. has approved the absorption merger of its wholly-owned subsidiary Sichuan Jishengtang Pharmaceutical Co., Ltd. with its wholly-owned subsidiary Sichuan Jishengtang Xingshang Biotechnology Co., Ltd., which will enhance operational efficiency and optimize resource allocation [1][2]. Group 1 - The board of directors approved the merger on April 25, 2025, and the merger will not change the name, shareholding structure, or registered capital of Jishengtang [1][2]. - The merger aims to improve operational efficiency, reduce management costs, and align with the company's development strategy for sustainable growth [2]. - The financial statements of both the merging and merged entities are already included in the company's consolidated financial statements, ensuring no substantial impact on overall business development or profitability [2].